Cargando…
Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.
A new bisphosphonate, disodium dihydrogen (cycloheptylamino) methylene bisphosphonate monohydrate (YM175), was compared with 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (AHPrBP) and 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) in terms of its effect on tumour induced osteolysis using a bladder...
Autores principales: | Nemoto, R., Nishijima, Y., Uchida, K., Koiso, K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968426/ https://www.ncbi.nlm.nih.gov/pubmed/8494721 |
Ejemplares similares
-
Inhibition of Osteoclast Differentiation and Bone Resorption by Bisphosphonate-conjugated Gold Nanoparticles
por: Lee, Donghyun, et al.
Publicado: (2016) -
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma
por: Kurabayashi, Atsushi, et al.
Publicado: (2015) -
Therapeutic targeting of osteoclasts by osteoprotegerin and bisphosphonates leads to a reduction of TNFalpha-mediated bone resorption
por: Redlich, K, et al.
Publicado: (2001) -
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines
por: Koshimune, Ryuichiro, et al.
Publicado: (2007) -
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
por: Sato, K, et al.
Publicado: (2006)